Based on previous studies, we investigated whether cilengitide (cRGDfV), a derivative of cRGDfK, enhances the inhibitory effect of gefitinib on cell proliferation and the TGF-β1-induced EMT in NSCLC cells. Here, TGFB1 is linked to non-small cell lung carcinoma.